Oncology Institute (TOIIW) Asset Writedowns and Impairment (2021 - 2023)

Oncology Institute has reported Asset Writedowns and Impairment for 3 years, with the latest figure at $2.0 million in Q4 2023.

• For the quarter ending Q4 2023, Asset Writedowns and Impairment rose 2587.84% year-over-year to $2.0 million; the trailing twelve-month figure through Sep 2024 stood at $2.0 million (up 1794.29% YoY), and the FY2023 full-year result was $2.0 million, up 324.37% from the prior year.
• Asset Writedowns and Impairment for Q4 2023 stood at $2.0 million, up from $33000.0 in the prior quarter.
• The five-year high for Asset Writedowns and Impairment was $2.0 million in Q4 2023, with the low at -$722000.0 in Q2 2021.
• Historically, Asset Writedowns and Impairment has averaged $189000.0 across 3 years, with a median of $74000.0 in 2022.
• The largest YoY upside for Asset Writedowns and Impairment was 2587.84% in 2023 against a maximum downside of 102.86% in 2023.
• Oncology Institute's Asset Writedowns and Impairment stood at $250000.0 in 2021, then plunged by 70.4% to $74000.0 in 2022, then soared by 2587.84% to $2.0 million in 2023.
• The last three Asset Writedowns and Impairment figures came in at $2.0 million (Q4 2023), $33000.0 (Q3 2023), and -$3000.0 (Q2 2023), per Business Quant data.